help button home button Endocrine Society JCEM
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS

This Article
Right arrow Full Text (PDF)
Right arrow Submit a related Letter to the Editor
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow Request Copyright Permission
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Bonnet, P.
Right arrow Articles by Hennen, G.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Bonnet, P.
Right arrow Articles by Hennen, G.

Journal of Clinical Endocrinology & Metabolism, Vol 77, 1203-1208, Copyright © 1993 by Endocrine Society


ARTICLES

Benign prostatic hyperplasia and normal prostate aging: differences in types I and II 5 alpha-reductase and steroid hormone receptor messenger ribonucleic acid (mRNA) levels, but not in insulin-like growth factor mRNA levels

P Bonnet, E Reiter, M Bruyninx, B Sente, D Dombrowicz, J de Leval, J Closset and G Hennen
Laboratoire d'Endocrinologie, Universite de Liege, Belgium.

Benign prostatic hyperplasia (BPH) is so common in elderly men that the development of adenomatous nodules in this organ can be seen as a normal age-dependent process. In this work, we used Northern blotting to compare the levels of androgen, estrogen, and insulin-like growth factor-I (IGF-I) receptor in young (age range, 23-33; n = 3), old normal (age range, 52-80; n = 3), and BPH-affected subjects (age range, 66-87; n = 15). We have also investigated in these groups the expression of genes coding for the two 5 alpha-reductases (types I and II), aromatase, IGF-I, and IGF-II. Our results show significantly increased levels of IGF mRNA in old healthy and BPH-affected subjects; the respective rises for IGF-I, IGF-II, and IGF-I receptor mRNAs were 3.0-, 2.9-, and 1.5-fold (BPH) and 2.7-, 2.4-, and 1.8-fold (old normal controls). For estrogen receptor, androgen receptor, and type I and II 5 alpha-reductase mRNAs, a marked but opposite effect was observed in adenomatous tissues only; the respective levels were 2.2-, 1.8-, 3.9-, and 1.7-fold lower than those in young adult subjects, whereas no significant differences were recorded between the two normal groups. Morphometric analysis of each tissue specimen confirmed the significantly lower epithelium/stroma ratio in adenomas compared to young or old healthy tissues. Together, these observations suggest that prostatic adenomas may result from at least two conjugate processes: one characterized by a drop in the mRNA levels of steroid hormone receptors, which might be associated with a lower epithelium/stroma ratio, and another characterized by normal aging phenomena, of which the increased production of IGFs and IGF-I receptor transcripts could be biochemical markers.


This article has been cited by other articles:


Home page
J. Biol. Chem.Home page
V. X. Fu, S. R. Schwarze, M. L. Kenowski, S. LeBlanc, J. Svaren, and D. F. Jarrard
A Loss of Insulin-like Growth Factor-2 Imprinting Is Modulated by CCCTC-binding Factor Down-regulation at Senescence in Human Epithelial Cells
J. Biol. Chem., December 10, 2004; 279(50): 52218 - 52226.
[Abstract] [Full Text] [PDF]


Home page
Journals of Gerontology Series A: Biological Sciences and Medical SciencesHome page
A. M. Matsumoto
Andropause: Clinical Implications of the Decline in Serum Testosterone Levels With Aging in Men
J. Gerontol. A Biol. Sci. Med. Sci., February 1, 2002; 57(2): M76 - 99.
[Full Text]


Home page
J. Clin. Endocrinol. Metab.Home page
S. Monti, F. Di Silverio, R. Iraci, C. Martini, S. Lanzara, P. Falasca, M. Poggi, A. Stigliano, F. Sciarra, and V. Toscano
Regional Variations of Insulin-Like Growth Factor I (IGF-I), IGF-II, and Receptor Type 1 in Benign Prostatic Hyperplasia Tissue and Their Correlation with Intraprostatic Androgens
J. Clin. Endocrinol. Metab., April 1, 2001; 86(4): 1700 - 1706.
[Abstract] [Full Text]


Home page
J. Clin. Endocrinol. Metab.Home page
S. M. Harman, E. J. Metter, M. R. Blackman, P. K. Landis, and H. B. Carter
Serum Levels of Insulin-Like Growth Factor I (IGF-I), IGF-II, IGF-Binding Protein-3, and Prostate-Specific Antigen as Predictors of Clinical Prostate Cancer
J. Clin. Endocrinol. Metab., November 1, 2000; 85(11): 4258 - 4265.
[Abstract] [Full Text]


Home page
EndocrinologyHome page
S. E. Damon, L. Maddison, J. L. Ware, and S. R. Plymate
Overexpression of an Inhibitory Insulin-Like Growth Factor Binding Protein (IGFBP), IGFBP-4, Delays Onset of Prostate Tumor Formation
Endocrinology, August 1, 1998; 139(8): 3456 - 3464.
[Abstract] [Full Text] [PDF]


Home page
Mol. Pharmacol.Home page
J.-H. Guh, T.-L. Hwang, F.-N. Ko, S.-C. Chueh, M.-K. Lai, and C.-M. Teng
Antiproliferative Effect in Human Prostatic Smooth Muscle Cells by Nitric Oxide Donor
Mol. Pharmacol., March 1, 1998; 53(3): 467 - 474.
[Abstract] [Full Text]




HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Endocrinology Endocrine Reviews J. Clin. End. & Metab.
Molecular Endocrinology Recent Prog. Horm. Res. All Endocrine Journals
Copyright © 1993 by The Endocrine Society